Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Nasopharyngeal carcinoma鼻咽癌

ICD-10: C11 — Malignant neoplasm of nasopharynx

Group: Cancer Specialty: Otorhinolaryngology, Radiation Oncology

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
鼻咽癌
English name
Malignant neoplasm of nasopharynx

Values written in Chinese are quoted as published by the source.

Also known as

  • NPC

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 Not applicable Not applicable 不适用 —
Radiotherapy 放疗 50000 – 62000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 15000 – 27000 CNY Average per case (full course) 全病程例均 2019–2023
Targeted therapy 靶向 20000 – 40000 CNY Per-item price 项目价 2024–2025
Immunotherapy 免疫 32043 – 66993 CNY Per-item price 项目价 2024–2025

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 66993 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 56.2% 95% CI 55.6–56.9

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    4 more published studies

    PubMed indexes 6 papers on this condition that name this hospital.

    Also ranked: Ophthalmology #3 in the Fudan list.

  2. Beijing Tongren Hospital首都医科大学附属北京同仁医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

    Also ranked: Ophthalmology #2 in the Fudan list.

  3. Chinese PLA General Hospital中国人民解放军总医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    Research platform

    Also ranked: General Surgery #5, Urology #1, Gastroenterology #4 in the Fudan list.

  4. Peking Union Medical College Hospital中国医学科学院北京协和医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Also ranked: General Surgery #1, Urology #8, Gynecology #1 in the Fudan list.

  5. The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院

    Guangzhou 广州市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #8, Gynecology #9, Gastroenterology #8 in the Fudan list.

  6. Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    Also ranked: Ophthalmology #6 in the Fudan list.

  7. Shanghai Sixth People's Hospital上海市第六人民医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

  8. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Nasopharyngeal carcinoma may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study Induction Chemotherapy Combined With Serplulimab Induction/Maintenance Therapy and Omission of Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma (UNION-NPC-001): A Multicenter, Open-Label, Randomized, Controlled, Phase III, Non-Inferiority Clinical Trial

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT07177443

  2. Study Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma

    Lead investigator
    Ying Wang · Associate Director of Chongqing University Cancer Hospital
    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06167109

  3. Study Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma

    Lead investigator
    Yaqian Han · Professor
    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06321939

  4. Study Proton Therapy Versus Photon Therapy for the Treatment of Nasopharyngeal Carcinoma: A Prospective, Open-Label, Multicenter, Phase III Non-Inferiority Clinical Trial

    Lead investigator
    Man Hu · Chief physician
    Hospital
    Shandong Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07000643

  5. Study Immune Score Based Radiomics in Nasopharyngeal Carcinoma (IMRAN Study)

    Hospital
    Renmin Hospital of Wuhan University
    Status
    Recruiting
    Registry
    NCT05126160
8 more registered studies

  1. Study QL1706 (Iparomlimab and Tuvonralimab Injection,PD-1/ CTLA-4 Bi-specific Antibody) Combined With Chemoradiotherapy Versus Chemoradiotherapy Alone in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma：A Randomized, Controlled, Multicenter Phase III Clinical Study.

    Lead investigator
    Jun Ma, MD · Professor
    Hospital
    Xiangya Hospital of Central South University
    Status
    Recruiting
    Registry
    NCT06749899

  2. Study Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition: A Prospective, Multicenter, Phase III Randomized Control Clinical Trial

    Lead investigator
    Zhao Chong · Prof.
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT04436965

  3. Study Development and Multicenter Validation of a Deep Learning Model Based on Whole Slide Imaging and Magnetic Resonance Imaging of the Nasopharynx and Lymph Nodes to Predict Distant Metastases at Diagnosis in Nasopharyngeal Carcinoma

    Lead investigator
    Pu-Yun OuYang · Associate Chief Physician
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT06831357

  4. Study TPC Versus GP Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma, a Multi-center Phase II Randomized Trial

    Lead investigator
    Hai-Qiang Mai,MD,PhD · Professor
    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT06301165

  5. Study A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT05956587

  6. Study Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II, Multicenter, Single-Arm Clinical Trial

    Lead investigator
    Jun Ma, MD · Principal Investigator
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Not yet recruiting
    Registry
    NCT07064902

  7. Study A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

    Lead investigator
    Yangkun Luo · Director
    Hospital
    Sichuan Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07062484

  8. Study Efficacy of Intranasal Corticosteroid Spray in Preventing Otitis Media With Effusion After Radiotherapy for Nasopharyngeal Carcinoma: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Not yet recruiting
    Registry
    NCT07189572

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 21 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Shanghai Sixth People's Hospital上海市第六人民医院 Shanghai 上海市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.6thhosp.com/content/news/11/vinfor
Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院 Shanghai 上海市 Otorhinolaryngology 耳鼻喉科 Level B https://www.fdeent.org/major/news/info/id/907.html
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院 Beijing 北京市 Radiation Oncology 放射治疗科 Level B https://www.cicams.ac.cn/news/401.html
Beijing Hospital北京医院 Beijing 北京市 Radiation Oncology 放射治疗科 Level B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University First Hospital北京大学第一医院 Beijing 北京市 Radiation Oncology 放射治疗科 Level B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 Otorhinolaryngology 耳鼻喉科 · Radiation Oncology 肿瘤放疗科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
West China Hospital, Sichuan University四川大学华西医院 Chengdu 成都市 Otorhinolaryngology 耳鼻喉科 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Sichuan Cancer Hospital四川省肿瘤医院 Chengdu 成都市 Radiation Oncology 放射治疗科 Level B https://www.sichuancancer.org/yygk/yyjs.htm
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Otorhinolaryngology 耳鼻咽喉科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Shandong Provincial Hospital山东省立医院 Jinan 济南市 Otorhinolaryngology 耳鼻咽喉科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院 Guangzhou 广州市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.gzsys.org.cn/basic/453
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 Guangzhou 广州市 Radiation Oncology 放射治疗科 Level B https://www.sysucc.org.cn/node/8565
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Otorhinolaryngology 耳鼻咽喉科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 Guangzhou 广州市 Otorhinolaryngology 耳鼻喉科 Level B https://www.gyfyy.com/cn/job/a_108951.html
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology华中科技大学同济医学院附属协和医院 Wuhan 武汉市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.whuh.com/Science/major/gjlczdzkb/2.htm
Second Xiangya Hospital of Central South University中南大学湘雅二医院 Changsha 长沙市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.xyeyy.com/655/656/664/
Xiangya Hospital of Central South University中南大学湘雅医院 Changsha 长沙市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.xiangya.com.cn/zdzk.html
Hunan Cancer Hospital湖南省肿瘤医院 Changsha 长沙市 Radiation Oncology 放疗科（国家级培育项目） Level B https://hnca.org.cn/wap/zdks/
First Hospital of China Medical University中国医科大学附属第一医院 Shenyang 沈阳市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.cmu1h.com/features/specialty
The First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 Chongqing 重庆市 Otorhinolaryngology 耳鼻咽喉科 Level B https://www.hospital-cqmu.com/gzb/yygk/yyjj.htm
Chongqing University Cancer Hospital重庆大学附属肿瘤医院 Chongqing 重庆市 Radiation Oncology 肿瘤放射治疗科 Level B https://www.cqch.cn/sitemap

21 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 7 ICD codes
Version Code Name in that version
ICD-10-WHO C11 Malignant neoplasm of nasopharynx
ICD-10-WHO C11.0 Superior wall of nasopharynx
ICD-10-WHO C11.1 Posterior wall of nasopharynx
ICD-10-WHO C11.2 Lateral wall of nasopharynx
ICD-10-WHO C11.3 Anterior wall of nasopharynx
ICD-10-WHO C11.8 Overlapping lesion of nasopharynx
ICD-10-WHO C11.9 Nasopharynx, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24